BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

bioRASI to Exhibit at the 2012 GPhA Annual Meeting in Orlando, FL


2/22/2012 8:19:52 AM

AVENTURA, FL--(Marketwire - February 21, 2012) - bioRASI, a full service, global Contract Research Organization (CRO), announced today that they will participate at the 2012 GPhA Annual Meeting in Orlando, Florida on February 22 - 24th. bioRASI will be exhibiting at booth #6 and will showcase its strategies and solutions for optimizing ophthalmic drugs development programs.

bioRASI will be introducing a new ophthalmology issue in their White Papers Series highlighting clinical endpoint ANDA Program Optimization techniques for the generics and specialty pharmaceutical industry.

"The share of ophthalmic drugs within most generic pipelines has been growing rapidly. bioRASI has emerged as the leader in conducting ophthalmology clinical studies," said Dr. Boris Reznik, Chairman of bioRASI. "Our Ophthalmology Program Management team consists of several MDs and MDs/PhDs in ophthalmology. This background coupled with many years of ophthalmic clinical trials experience makes bioRASI's ability to optimize these programs second to none."

bioRASI publishes the white papers several times a year, addressing and analyzing different aspects of optimization, and making them available on their website, at marketing and technical conferences and through other established electronic publishing services.

About bioRASI

bioRASI is a Full Service Global CRO. Its Generics Division is uniquely focused on clinical endpoint ANDA and 505(b)(2) programs. This experience and expertise allow bioRASI to facilitate obtaining FDA approvals by delivering high quality regulatory and clinical strategies, solutions and services, while saving their clients critical time. bioRASI's services include program management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI leverages its unique access to the world's largest facilities and patient populations in the U.S., Europe and Asia to achieve unparalleled scientific, clinical and business results at significantly lower costs. bioRASI is headquartered in Aventura, FL and has regional offices across in the U.S and overseas.


Contact
Bill Doyle
(786) 388-0700
Email Contact
www.biorasi.com



Read at BioSpace.com

bioRASI
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES